headaches and tirzepatide Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring GLP1/trizipatide for chronic migraines relief?

For the outcome of NAION, the mean (SD) follow-up time was 674.8 (49.2) days for the semaglutide or tirzepatide group and 647.5 (74.3) days for the comparison group

The near-balanced peptide was shown to be ~2-fold less potent at GLP-1R and ~10 fold less potent at GCGR than native ligands in cAMP synthesis (75)

Clinical trial results showed participants taking oral Wegovy achieved an average weight loss of approximately 17%, highlighting its potential to expand treatment options for people living with obesity or overweight with weight-related conditions

For the treatment of obesity, GLP-1RAs and GIP/ GLP-1RAs are indicated in patients with a body mass index (BMI) 30 kg m 2 , or 27 kg m 2 in the presence of at least one weight-related comorbidity, to support weight reduction [23]

But once patients enter the health-care system for treatment, doctors can guide them through all options whether that's an injection, metabolic surgery, or structured diet and exercise programs, Apovian said

[1] [4] As with many subcutaneous injections, skin reactions at the injection site are among the most frequently reported adverse effects